Mazabraud's Syndrome: A Case Report and Up-To-Date Literature Review

Author(s): Fabio Vescini*, Alberto Falchetti, Veronica Tonelli, Maria Carpentieri, Claudia Cipri, Roberta Cosso, Elda Kara, Vincenzo Triggiani, Franco Grimaldi

Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders

Volume 19 , Issue 6 , 2019

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Objective: Mazabraud's syndrome is a rare form of bone fibrous dysplasia associated with intramuscular myxomas. Fibrous dysplasia, is generally localized to pelvis and femur and it results in a fragile bone with deformities, pain, pathological fractures and functional impairment. Intramuscular myxomas, are rare benign mesenchymal neoplasms that exceptionally may evolve to malignant forms.

Methods: This case report describes a 66-year-old woman with Mazabraud’s Syndrome (MS), characterized both by monostotic right femur fibrous dysplasia and by a solitary intramuscular myxoma at the right quadriceps muscle, that underwent a long-term treatment (4 years) with intravenous zoledronic acid.

Results: Zoledronic acid therapy rapidly lowered bone pain together with a reduction of intramuscular myxoma volume, but did not affect the extension of fibrous dysplasia. No adverse effects have been observed during treatment.

Conclusion: Highly active bisphosphonates are commonly used for the treatment of bone metabolic disorders and they are generally well tolerated. Zoledronic acid may represent a promising alternative to surgical intervention in MS, although its use in rare form of bone fibrous dysplasias is still controversial.

Keywords: Mazabraud's syndrome, fibrous dysplasia, intramuscular myxoma, zoledronic acid, GNAS1 gene mutations, benign mesenchymal neoplasms.

Henschen, F. Fall von ostitis Fibrosa mit multiplen Tumoren in der umgebenden Muskulatur. Verh. Dtsch. Ges. Pathol., 1926, 21, 93-97.
Mazabraud, A.; Girard, J. [A peculiar case of fibrous dysplasia with osseous and tendinous localizations] Rev. Rhum. Mal. Osteoartic., 1957, 24(9-10), 652-659.
[PMID: 13518962]
Enzinger, F.M. Intramuscular myxoma; A review and follow-up study of 34 cases. Am. J. Clin. Pathol., 1965, 43, 104-113.
[] [PMID: 14253111]
Yaligod, V. M, A.S. Intramuscular Myxoma - A Rare Tumor. J. Orthop. Case Rep., 2013, 3(4), 38-41.
[] [PMID: 27298930]
Miettinen, M.; Höckerstedt, K.; Reitamo, J.; Tötterman, S. Intramuscular myxoma--a clinicopathological study of twenty-three cases. Am. J. Clin. Pathol., 1985, 84(3), 265-272.
[] [PMID: 4036856]
Zoccali, C.; Teori, G.; Prencipe, U.; Erba, F. Mazabraud’s syndrome: A new case and review of the literature. Int. Orthop., 2009, 33(3), 605-610.
[] [PMID: 18214477]
Fu, S.; Tian, Z.; Zhang, C.; He, Y. Monosotic fibrous dysplasia and solitary intramuscular myxoma of the head and neck: A unique presentation of Mazabraud’s syndrome and a literature review. Oncol. Lett., 2015, 10(5), 3087-3094.
[] [PMID: 26722294]
Tabareau-Delalande, F.; Collin, C.; Gomez-Brouchet, A.; Decouvelaere, A.V.; Bouvier, C.; Larousserie, F.; Marie, B.; Delfour, C.; Aubert, S.; Rosset, P.; de Muret, A.; Pagès, J.C.; de Pinieux, G. Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod. Pathol., 2013, 26(7), 911-921.
[] [PMID: 23370769]
Cox, J.L.; Cushman-Vokoun, A.M.; McGarry, S.V.; Kozel, J.A. Two cases of Mazabraud syndrome and identification of a GNAS R201H mutation by next-generation sequencing. Virchows Arch., 2017, 470(5), 589-593.
[] [PMID: 28258512]
Dal Cin, P.; Sciot, R.; Brys, P.; De Wever, I.; Dorfman, H.; Fletcher, C.D.; Jonsson, K.; Mandahl, N.; Mertens, F.; Mitelman, F.; Rosai, J.; Rydholm, A.; Samson, I.; Tallini, G.; Van den Berghe, H.; Vanni, R.; Willen, H. Recurrent chromosome aberrations in fibrous dysplasia of the bone: A report of the CHAMP study group. CHromosomes And MorPhology. Cancer Genet. Cytogenet., 2000, 122(1), 30-32.
[] [PMID: 11104029]
Beyer Nardi, N.; da Silva Meirelles, L. Mesenchymal stem cells: Isolation, in vitro expansion and characterization. In Wobus, A. M.; Boheler, K. Stem Cells. Handbook of Experimental Pharmacology, 2006, 174, 249-82
Iwasko, N.; Steinbach, L.S.; Disler, D.; Pathria, M.; Hottya, G.A.; Kattapuram, S.; Varma, D.G.; Kumar, R. Imaging findings in Mazabraud’s syndrome: seven new cases. Skeletal Radiol., 2002, 31(2), 81-87.
[] [PMID: 11828328]
Muthusamy, S.; Conway, S.A.; Temple, H.T. Five polyostotic conditions that general orthopedic surgeons should recognize (or should not miss). Orthop. Clin. North Am., 2014, 45(3), 417-429.
[] [PMID: 24975767]
O’Sullivan, G.J.; Carty, F.L.; Cronin, C.G. Imaging of bone metastasis: An update. World J. Radiol., 2015, 7(8), 202-211.
[] [PMID: 26339464]
Prada, E.J.; Hassan, K.H.; Brandi, M.L.; Falchetti, A. Polyostotic form of fibrous dysplasia in a 13 years old Colombian girl showing clinical and biochemical response to neridronate intravenous therapy. Clin. Cases Miner. Bone Metab., 2009, 6(3), 264-265.
[PMID: 22461257]
Bancroft, L.W.; Kransdorf, M.J.; Menke, D.M.; O’Connor, M.I.; Foster, W.C. Intramuscular myxoma: characteristic MR imaging features. AJR Am. J. Roentgenol., 2002, 178(5), 1255-1259.
[] [PMID: 11959742]
Luckman, S.P.; Hughes, D.E.; Coxon, F.P.; Graham, R.; Russell, G.; Rogers, M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res., 1998, 13(4), 581-589.
[] [PMID: 9556058]
Liens, D.; Delmas, P.D.; Meunier, P.J. Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet, 1994, 343(8903), 953-954.
[] [PMID: 7909013]
Ozdemir Kutbay, N.; Sarer Yurekli, B.; Kartal Baykan, E.; Baydur Sahin, S.; Saygili, F. Characteristics and Treatment Results of 5 Patients with Fi-brous Dysplasia and Review of the Literature. Case Rep. Endocrinol., 2015, 670809, 7.
Majoor, B.C.; Appelman-Dijkstra, N.M.; Fiocco, M.; van de Sande, M.A.; Dijkstra, P.S.; Hamdy, N.A. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia. J. Bone Miner. Res., 2017, 32(2), 264-276.
[] [PMID: 27649526]
Szymanski, C.; Bourgault, C.; Penel, N.; Maynou, C. Chondrosarcoma of the femur in Mazabraud’s syndrome: A first case study. Orthop. Traumatol. Surg. Res., 2015, 101(7), 875-878.
[] [PMID: 26498883]
Lane, J.M.; Khan, S.N.; O’Connor, W.J.; Nydick, M.; Hommen, J.P.; Schneider, R.; Tomin, E.; Brand, J.; Curtin, J. Bisphosphonate therapy in fibrous dysplasia. Clin. Orthop. Relat. Res., 2001, (382), 6-12.
[] [PMID: 11154006]
Wu, D.; Ma, J.; Bao, S.; Guan, H. Continuous effect with long-term safety in zoledronic acid therapy for polyostotic fibrous dysplasia with severe bone destruction. Rheumatol. Int., 2015, 35(4), 767-772.
[] [PMID: 25230905]

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2019
Page: [885 - 893]
Pages: 9
DOI: 10.2174/1871530319666181226103700

Article Metrics

PDF: 64
PRC: 1